Company
Granted marketing authorisation for DAYBU
Every investor coverage indicates participated in a round European Commission raised.
Companies European Commission acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Ursula von der Leyen | President | Women's Agenda |
Stories naming European Commission. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
European regulators have cleared Neuren's Rett syndrome drug DAYBU, the first such treatment authorised in the EU, with milestone payments due to the Melbourne biotech from licence partner Acadia.
A year-end list profiling women leaders worldwide, from presidents to tech founders; it recalls Airwallex's landmark capital raise and Mira Murati's new AI venture with its record seed round.
Also Forbes Australia
Calix-backed SOCRATCES project is trialling calcium looping for concentrated solar power storage, using Calix kiln technology at a Seville pilot plant funded by the European Commission's Horizon 2020 scheme.